Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Agonist ligands for the nuclear receptor peroxisome proliferator-activated receptor-γ have been shown to induce terminal differentiation of normal preadipocytes and human liposarcoma cells in vitro . Because the differentiation status of liposarcoma is predictive of clinical outcomes, modulation of the differentiation status of a tumor may favorably impact clinical behavior. We have conducted a clinical trial for treatment of patients with advanced liposarcoma by using the peroxisome proliferator-activated receptor-γ ligand troglitazone, in which extensive correlative laboratory studies of tumor differentiation were performed. We report here the results of three patients with intermediate to high-grade liposarcomas in whom troglitazone administration induced histologic and biochemical differentiation in vivo . Biopsies of tumors from each of these patients while on troglitazone demonstrated histologic evidence of extensive lipid accumulation by tumor cells and substantial increases in NMR-detectable tumor triglycerides compared with pretreatment biopsies. In addition, expression of several mRNA transcripts characteristic of differentiation in the adipocyte lineage was induced. There was also a marked reduction in immunohistochemical expression of Ki-67, a marker of cell proliferation. Together, these data indicate that terminal adipocytic differentiation was induced in these malignant tumors by troglitazone. These results indicate that lineage-appropriate differentiation can be induced pharmacologically in a human solid tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
Self-citation15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Self-citationmPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Cited by
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Adipose-derived stem cells for regenerative medicine
Gimble, J. M., Katz, A. J., & Bunnell, B. A. (2007) · Circulation Research · doi:10.1161/01.res.0000265074.83288.09 · Cited by 2,332
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Self-citationRoles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth
Rosen, E. D., & Spiegelman, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100034200 · Cited by 1,175
Self-citationOrphan Nuclear Receptors: From Gene to Function*
Giguère, V. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0378 · Cited by 855
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Self-citationHepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Peroxisome-proliferator-activated receptors and cancers: complex stories
Michalik, L., Desvergne, B., & Wahli, W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1254 · Cited by 573
Activation of PPAR and PPAR by Environmental Phthalate Monoesters
Hurst, C. H., & Waxman, D. J. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg145 · Cited by 510
Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer
Sarraf, P., Mueller, E., Smith, W. M., Wright, H. M., Kum, J. B., Aaltonen, L. A., de la Chapelle, A., Spiegelman, B. M., & Eng, C. (1999) · Molecular Cell · doi:10.1016/s1097-2765(01)80012-5 · Cited by 506
Self-citationThe role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Peroxisome proliferator-activated receptors: insight into multiple cellular functions
Escher, P., & Wahli, W. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00231-6 · Cited by 491
Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J.-Y., Le Cesne, A., Sanfilippo, R., Casieri, P., Collini, P., Dileo, P., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70175-4 · Cited by 454
Self-citationSources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review
Berebichez-Fridman, R., & Montero-Olvera, P. R. (2018) · Sultan Qaboos University Medical Journal · doi:10.18295/squmj.2018.18.03.002 · Cited by 450
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440
Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 426
Self-citationPPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
Murphy, G. J., & Holder, J. C. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01559-5 · Cited by 386
Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 374
Clinical and Molecular Spectrum of Liposarcoma
Lee, A. T. J., Thway, K., Huang, P. H., & Jones, R. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9598 · Cited by 372
Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E., & Spiegelman, B. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001297200 · Cited by 367
Self-citationPatel, L., Pass, I., Coxon, P., Downes, C. P., Smith, S. A., & Macphee, C. H. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00225-1 · Cited by 365
Differentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Peroxisome proliferator‐activated receptors in the cardiovascular system
Bishop‐Bailey, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703149 · Cited by 363
Corton, J. C., Anderson, S. P., & Stauber, A. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.491 · Cited by 341
Inflammation and the development of pancreatic cancer
Farrow, B., & Evers, B. M. (2002) · Surgical Oncology · doi:10.1016/s0960-7404(02)00015-4 · Cited by 338
PPARs: transcriptional effectors of fatty acids and their derivatives
Hihi, A. K., Michalik, L., & Wahli, W. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8467-x · Cited by 311
ACSL family: The regulatory mechanisms and therapeutic implications in cancer
Quan, J., Bode, A. M., & Luo, X. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174397 · Cited by 306
Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas
Marques, A. R., Espadinha, C., Catarino, A. L., Moniz, S., Pereira, T., Sobrinho, L. G., & Leite, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8756 · Cited by 305
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Skubitz, K. M., & D'Adamo, D. R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1409 · Cited by 277
Subbaramaiah, K., Lin, D. T., Hart, J. C., & Dannenberg, A. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007237200 · Cited by 275
RetractedDifferentiation Potential of Adipose Derived Adult Stem (ADAS) Cells
Gimble, J. M., & Guilak, F. (2003) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)58005-x · Cited by 271
The role of lipid metabolic reprogramming in tumor microenvironment
Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023) · Theranostics · doi:10.7150/thno.82920 · Cited by 270
Stem-cell hierarchy in skin cancer
Perez-Losada, J., & Balmain, A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1095 · Cited by 268
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228
“and has been shown in clinical trials to induce solid tumor differentiation of liposarcomas both in vitro as well as in patients with advanced disease [7, 8].”
BackgroundSelf-citationNatarajan, C., & Bright, J. J. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363832 · Cited by 208
Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126
15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells
Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H., & High, K. P. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200224-jlr200 · Cited by 103
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
Engaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
The Generation and Characterization of a Cell Line Derived from a Sporadic Renal Angiomyolipoma
Arbiser, J. L., Yeung, R., Weiss, S. W., Arbiser, Z. K., Amin, M. B., Cohen, C., Frank, D., Mahajan, S., Herron, G. S., Yang, J., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61720-8 · Cited by 32
Metadata
- Authors
- Demetri, G. D., Fletcher, C. D. M., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-03-30
- Volume
- 96
- Issue
- 7
- Pages
- 3951-3956
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2050352100
- Cited by
- 495
- References
- 27
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.